News | Avance Clinical Joins Medrio’s ‘Trial Talks’ Podcast about Why Clinical Trials are Thriving in Australia
July 30, 2020
The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical, joins Medrio’s new podcast series Trial Talks. Trial Talks season 1, episode 1 “Why Clinical Trials are Thriving in Australia” focuses on how Avance Clinical prepared for the pandemic, what tools were leveraged that allowed trial continuation, and why clinical trials are currently thriving in the region.
Medrio, Inc. is the leading provider of eClinical technology to
pharmaceutical, biotech, medical device, diagnostics, and animal health markets.
The first of the new Trial Talks podcast series features Avance
Clinical CEO Yvonne Lungershausen and Director of Business Development
Operations Sandrien Louwaars interviewed by Mike Novotny, CEO at Medrio.
Trial Talks is a
clinical trials podcast series hosted by Medrio thought leaders. Trial
Talks season one will focus on industry trends and challenges, unique
solutions, and the perseverance of the industry through one of our toughest
season 1, episode 1 “Why Clinical Trials are Thriving in Australia” focuses on
how Avance Clinical prepared for the pandemic, what tools were leveraged that
allowed trial continuation, and why clinical trials are currently thriving in
Medrio and Avance Clinical recently reached a milestone of supporting
150 clinical trials together.
Medrio and Avance Clinical’s successful partnership began in 2012 on a Phase I study with 103 patients and 14 sites, with Avance Clinical being Medrio’s first CRO partner in the Asia-Pacific.
Avance Clinical has utilized Medrio’s electronic data capture (EDC)
solution successfully for the past eight years supporting 158 Phase I studies,
6,047 patients, and 236 sites. The HRECs usual review cycle in Australia, which
takes only 4 to 8 weeks, coupled with Medrio’s ability to achieve FPI in less
than three weeks is a perfect combination for accelerating study starts, a
critical component to Phase I trials.
Yvonne Lungershausen, CEO at Avance Clinical said:
“Medrio has always been a wonderful partner to Avance Clinical. In
addition to their EDC, we’ve used their ePRO and Direct Capture solutions, and
we’re always impressed by not only their speed and flexibility but also their
support. We know that if we have a question or need assistance that it will be
addressed immediately and resolved quickly. Our partnership continues to
flourish through ongoing clinical trials. We also recently had a great
conversation with Medrio on their podcast, Trial Talks, about
Australia’s unique position in the midst of COVID-19. I look forward to the
continued success and growth of our partnership.”
Mike Novotny, CEO Medrio said:
“I’ve always been data-driven, and reaching the 150 trials milestone
speaks volumes about Medrio and Avance’s relationship. Trust is earned, and I’d
like to think that we’ve shown that we offer not only sophisticated clinical
trial technology but also pride in our work. Our support team is available 24/7
and I am always proud to hear our customers speak so highly of them.
At Medrio we always have the patients in mind, and the faster we can get
a trial up and running or provide support, the faster the patients in need will
have the drugs, therapies, or devices that they need. I enjoyed interviewing
Yvonne Lungershausen (CEO) and Sandrien Louwaars (Director of Business
Development Operations) for the first Trial Talks podcast episode. It
was fascinating to hear how Australia and New Zealand are operating in the
midst of a global pandemic, and it highlights the perseverance of the industry
and the Golden Age of pharma.”
Medrio is the leading provider of eClinical technology for pharma, device, and
diagnostics clinical trials. Founded in 2005, the company’s cloud-based EDC,
Direct Data Capture, eConsent, and ePRO solutions deliver fast, flexible, and
easy-to-use tools for the collection and management of clinical data and
patient-reported outcome responses. Study sponsors and Contract Research
Organizations have used Medrio extensively in clinical trials across a wide
array of therapeutic areas, with notable success in oncology, infectious
disease, and more. Medrio has extensive experience in all study phases and
leads the market in early-phase trials. The company serves over 600 customers
globally, with headquarters in San Francisco and offices in numerous domestic
and international locations. For more information, please visit http://www.medrio.com.
About Avance Clinical
Australia’s Avance Clinical has more than 20-years of experience and is one of
Australia’s leading Contract Research Organizations. Avance Clinical
facilitates quality drug development by aligning people, skills, and expertise
in the pursuit of drug development for a healthier world.
Avance Clinical is committed to providing high-quality clinical research
services with its highly experienced team.
The collective pool of knowledge and experience at Avance Clinical continually
grows through the careful selection of experts who also demonstrate passion in
their chosen field.
Avance Clinical offers high-quality services in an established clinical trial
ecosystem, that includes world-class Investigators and Sites able to access
specialized patient groups. Visit http://www.avancecro.com for more information.
Other benefits include:
1. The Government R&D grant means up to 43.5% rebate on clinical trial
2. Telehealth pivot during COVID-19 pandemic – speed and continuity
3. Site Initiation Visit (SIV) and Study Start achieved in 5 – 6 weeks
4. No IND required for clinical trials
5. Full GMP material is not mandated for Phase I clinical trials
6. Established clinical trial environment with world-class Investigators and
7. Established healthy subject databases and specialized patient populations
8. Five independent Phase 1 facilities across Australia including
hospital-based units for critical care
9. Major hospitals with world-class infrastructures and dedicated Clinical
Trial Units with a long track-record in FDA compliant research
10. Seasonal studies: Northern hemisphere Sponsors can conduct their studies
year-round by taking advantage of Australia’s counter-flu and allergy seasons